ONYX PHARMACEUTICALS INC 4

Accession 0001181431-13-052528

CIK 0001012140operating

View on SEC.gov Company Profile

Filed

Oct 2, 8:00 PM ET

Accepted

Oct 3, 9:30 PM ET

Size

29.1 KB

Accession

0001181431-13-052528

Insider Transaction Report

Form 4

Period: 2013-10-01

ONYX PHARMACEUTICALS INCONXX

WIERENGA WENDALL

Director

Transactions

Disposition from Tender
Common Stock
2013-10-01$125.00/sh−9,080$1,135,000→ 2,100 total
Disposition to Issuer
Stock Options
2013-10-01−10,000→ 0 total
Exercise: $32.93From: 2005-12-13Exp: 2014-12-13→ Common Stock (10,000 underlying)
Disposition to Issuer
Stock Options
2013-10-01−10,000→ 0 total
Exercise: $29.39From: 2006-12-13Exp: 2015-12-13→ Common Stock (10,000 underlying)
Disposition to Issuer
Stock Options
2013-10-01−5,000→ 0 total
Exercise: $35.18From: 2012-03-31Exp: 2021-03-31→ Common Stock (5,000 underlying)
Disposition to Issuer
Common Stock
2013-10-01$125.00/sh−2,100$262,500→ 0 total
Disposition to Issuer
Stock Options
2013-10-01−2,000→ 0 total
Exercise: $76.79From: 2013-07-25Exp: 2022-07-25→ Common Stock (2,000 underlying)
Disposition to Issuer
Stock Options
2013-10-01−5,000→ 0 total
Exercise: $11.86From: 2007-12-13Exp: 2016-12-13→ Common Stock (5,000 underlying)
Disposition to Issuer
Stock Options
2013-10-01−10,000→ 0 total
Exercise: $29.70From: 2009-12-15Exp: 2018-12-15→ Common Stock (10,000 underlying)
Disposition to Issuer
Stock Options
2013-10-01−1,452→ 0 total
Exercise: $28.55From: 2010-03-31Exp: 2019-03-31→ Common Stock (1,452 underlying)
Disposition to Issuer
Stock Options
2013-10-01−10,000→ 0 total
Exercise: $55.06From: 2008-12-13Exp: 2017-12-13→ Common Stock (10,000 underlying)
Disposition to Issuer
Stock Options
2013-10-01−5,000→ 0 total
Exercise: $30.28From: 2011-03-31Exp: 2020-03-31→ Common Stock (5,000 underlying)
Disposition to Issuer
Stock Options
2013-10-01−5,000→ 0 total
Exercise: $37.68From: 2013-03-30Exp: 2022-03-30→ Common Stock (5,000 underlying)
Disposition to Issuer
Stock Options
2013-10-01−5,000→ 0 total
Exercise: $88.86From: 2014-03-28Exp: 2023-03-27→ Common Stock (5,000 underlying)

Footnotes (2)

[F1]These restricted stock awards were cancelled at the effective time of the merger (the "Merger") pursuant to the Agreement and Plan of Merger, dated August 24, 2013, by and among Onyx Pharmaceuticals, Inc. ("Onyx"), Amgen Inc. and Arena Acquisition Company (the "Merger Agreement") in exchange for an aggregate cash payment equal to the number of shares of Onyx's common stock underlying such restricted stock awards multiplied by the per share purchase price of $125.00.
[F2]Represents options to purchase Onyx's common stock that were subject to vesting over time but were cancelled in the Merger in exchange for a cash payment in the amount by which the per share purchase price of $125.00 exceeded the exercise price of the option as of the effective time of the Merger.

Documents

1 file

4
rrd392202.xmlPrimary
FORM 4

Issuer

ONYX PHARMACEUTICALS INC

CIK 0001012140

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0001012140

Filing Metadata

Form type: 4
Filed: Oct 2, 8:00 PM ET
Accepted: Oct 3, 9:30 PM ET
Size: 29.1 KB

View on SEC.gov